| scholarly article | Q13442814 |
| P2093 | author name string | Stephen J Forman | |
| David Senitzer | |||
| Karl Gaal | |||
| Leslie Popplewell | |||
| Joycelynne M Palmer | |||
| Auayporn Nademanee | |||
| Neil Kogut | |||
| Sandra Thomas | |||
| Jasmine Zain | |||
| Maria Delioukina | |||
| Margaret O'Donnell | |||
| Ni-Chun Tsai | |||
| P2860 | cites work | The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997 | Q28143029 |
| Statistical methods in cancer research. Volume II--The design and analysis of cohort studies | Q29615413 | ||
| Phase IIb multicenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma | Q33375600 | ||
| Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma | Q33386623 | ||
| Reinventing bone marrow transplantation: reducing toxicity using nonmyeloablative, preparative regimens and induction of graft-versus-malignancy | Q33585002 | ||
| Estimation of failure probabilities in the presence of competing risks: new representations of old estimators | Q33594562 | ||
| Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group | Q33773306 | ||
| Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma | Q34288599 | ||
| WHO-EORTC classification for cutaneous lymphomas | Q34391006 | ||
| International peripheral T-cell and natural killer/T-cell lymphoma study: pathology findings and clinical outcomes | Q34594231 | ||
| Graft-vs.-lymphoma effect in various histologies of non-Hodgkin's lymphoma | Q35808430 | ||
| Graft-versus-lymphoma effects: clinical review, policy proposals, and immunobiology | Q35866819 | ||
| Eight-year experience with allogeneic stem cell transplantation for relapsed follicular lymphoma after nonmyeloablative conditioning with fludarabine, cyclophosphamide, and rituximab | Q36219690 | ||
| Hematopoietic SCT for peripheral T-cell lymphoma | Q37303846 | ||
| Follicular non-Hodgkin lymphoma: long-term results of stem-cell transplantation | Q37357735 | ||
| Update on treatment of cutaneous T-cell lymphoma | Q37521546 | ||
| Histone deacetylase inhibitor panobinostat induces clinical responses with associated alterations in gene expression profiles in cutaneous T-cell lymphoma | Q40070617 | ||
| Phase 2 study of alemtuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome | Q40566975 | ||
| Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. | Q40754916 | ||
| Improved survival in lymphoma patients receiving sirolimus for graft-versus-host disease prophylaxis after allogeneic hematopoietic stem-cell transplantation with reduced-intensity conditioning | Q41876102 | ||
| T-cell depletion and autologous stem cell transplantation in the management of tumour stage mycosis fungoides with peripheral blood involvement | Q43734642 | ||
| Peripheral T-cell lymphomas have a worse prognosis than B-cell lymphomas: a prospective study of 361 immunophenotyped patients treated with the LNH-84 regimen. The GELA (Groupe d'Etude des Lymphomes Agressives). | Q44257311 | ||
| Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation | Q44827099 | ||
| Graft-versus-lymphoma effect in relapsed peripheral T-cell non-Hodgkin's lymphomas after reduced-intensity conditioning followed by allogeneic transplantation of hematopoietic cells. | Q44915322 | ||
| Characterization of peripheral T-cell lymphomas in a single North American institution by the WHO classification | Q45059029 | ||
| Allogeneic hematopoietic cell transplantation for patients with mycosis fungoides and Sézary syndrome: a retrospective analysis of the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. | Q45886829 | ||
| Comparison of reduced-intensity and conventional myeloablative regimens for allogeneic transplantation in non-Hodgkin's lymphoma | Q46281774 | ||
| Prognostic factors and treatment of patients with T-cell non-Hodgkin lymphoma: the M. D. Anderson Cancer Center experience | Q46426412 | ||
| A phase I clinical trial of the histone deacetylase inhibitor belinostat in patients with advanced hematological neoplasia | Q46569093 | ||
| Durable clinical, cytogenetic, and molecular remissions after allogeneic hematopoietic cell transplantation for refractory Sezary syndrome and mycosis fungoides | Q46681083 | ||
| High-dose therapy and autologous stem cell transplant does not result in long-term disease-free survival in patients with recurrent chemotherapy-sensitive ALK-negative anaplastic large-cell lymphoma | Q47990492 | ||
| Allogeneic haematopoietic stem cell transplantation in relapsed or refractory anaplastic large cell lymphoma of children and adolescents--a Berlin-Frankfurt-Münster group report. | Q52933556 | ||
| All aggressive lymphoma subtypes do not share similar outcome after front-line autotransplantation: a matched-control analysis by the Groupe d'Etude des Lymphomes de l'Adulte (GELA). | Q53281895 | ||
| Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): results from the Non-Hodgkin's Lymphoma Classification Project. | Q53317384 | ||
| Prognostic significance of T-cell phenotype in aggressive non-Hodgkin's lymphomas. Groupe d'Etudes des Lymphomes de l'Adulte (GELA). | Q53353633 | ||
| Myeloablative allogeneic hematopoietic stem cell transplantation for non-Hodgkin lymphoma: a nationwide survey in Japan. | Q53633520 | ||
| P-glycoprotein expression and multidrug resistance in cutaneous T-cell lymphoma. | Q54033163 | ||
| Graft-versus-lymphoma effect for aggressive T-cell lymphomas in adults: a study by the Société Francaise de Greffe de Moëlle et de Thérapie Cellulaire. | Q55239369 | ||
| The World Health Organization Classification of Neoplastic Diseases of the Hematopoietic and Lymphoid Tissues | Q55981046 | ||
| Allogeneic Hematopoietic Stem Cell Transplantation for Peripheral T Cell Lymphomas; Evidence of Graft-Versus-T Cell Lymphoma Effect | Q58011217 | ||
| Allogeneic bone marrow transplantation in aggressive non-Hodgkin's lymphoma (excluding Burkitt and lymphoblastic lymphoma): a series of 73 patients from the SFGM database | Q61053545 | ||
| Peripheral T-cell lymphoma unspecified (PTCL-U): a new prognostic model from a retrospective multicentric clinical study | Q61774252 | ||
| Clinical efficacy of zanolimumab (HuMax-CD4): two phase 2 studies in refractory cutaneous T-cell lymphoma | Q61833759 | ||
| Prospective comparative trial of autologous versus allogeneic bone marrow transplantation in patients with non-Hodgkin's lymphoma | Q72103663 | ||
| Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression | Q73695727 | ||
| Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project | Q77306442 | ||
| Histology impacts the outcome of peripheral T-cell lymphomas after high dose chemotherapy and stem cell transplant | Q80927255 | ||
| Allogeneic stem cell transplantation is able to induce long-term remissions in angioimmunoblastic T-cell lymphoma: a retrospective study from the lymphoma working party of the European group for blood and marrow transplantation | Q84264294 | ||
| P433 | issue | 8 | |
| P921 | main subject | non-Hodgkin lymphoma | Q1138590 |
| P304 | page(s) | 1463-1473 | |
| P577 | publication date | 2011-06-24 | |
| P1433 | published in | Leukemia & Lymphoma | Q6534493 |
| P1476 | title | Allogeneic hematopoietic cell transplant for peripheral T-cell non-Hodgkin lymphoma results in long-term disease control | |
| P478 | volume | 52 |
| Q91152150 | Allogeneic hematopoietic stem cell transplantation for patients with relapsed/refractory systemic anaplastic large cell lymphoma. A retrospective analysis of the Lymphoma Working Party of the European Society for Blood and Marrow Transplantation |
| Q102063583 | Allogeneic stem cell transplantation in poor prognosis peripheral T-cell lymphoma: the impact of different donor type on outcome |
| Q38132821 | Current state of art for transplantation paradigms in peripheral T-cell lymphomas. |
| Q37938531 | Current status of allogeneic transplantation for aggressive non-Hodgkin lymphoma |
| Q38561684 | Development and evaluation of a specifically designed website for haematopoietic stem cell transplant patients in Leeds |
| Q41106212 | Effect of immune modulation in relapsed peripheral T-cell lymphomas after post-allogeneic stem cell transplantation: a study by the Société Française de Greffe de Moelle et de Thérapie Cellulaire (SFGM-TC). |
| Q37271019 | First-line therapy of peripheral T-cell lymphoma: extension and long-term follow-up of a study investigating the role of autologous stem cell transplantation |
| Q37122302 | Hematopoietic cell transplantation for systemic mature T-cell non-Hodgkin lymphoma |
| Q33608520 | Outcomes of related donor HLA-identical or HLA-haploidentical allogeneic blood or marrow transplantation for peripheral T cell lymphoma |
| Q38108320 | Reduced-intensity conditioning allogeneic stem cell transplantation in malignant lymphoma: current status |
Search more.